These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 219673

  • 21. [Familial hyperlipoproteinemia type III].
    Patsch JR, Patsch W, Sailer S, Braunsteiner H.
    Dtsch Med Wochenschr; 1976 Oct 29; 101(44):1612-9. PubMed ID: 185039
    [No Abstract] [Full Text] [Related]

  • 22. Antihyperlipidaemic agents.
    Witte EC.
    Prog Med Chem; 1975 Oct 29; 11():119-92. PubMed ID: 165566
    [No Abstract] [Full Text] [Related]

  • 23. Clinical and metabolic effects of pentaerythritol tetranicotinate(Perycit)and a comparison with plain nicotinic acid.
    Olsson AG, Orö L, Rössner S.
    Atherosclerosis; 1974 Oct 29; 19(1):61-73. PubMed ID: 4359183
    [No Abstract] [Full Text] [Related]

  • 24. Comparative study of several hypolipidemic agents related to clofibrate.
    Beaumont V, Buxtorf JC, Jacotot B, Beaumont JL.
    Atherosclerosis; 1974 Oct 29; 20(2):141-53. PubMed ID: 4369878
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J, Bang HO.
    Acta Med Scand; 1976 Oct 29; 200(1-2):55-58. PubMed ID: 183462
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P, Schwandt P.
    Verh Dtsch Ges Inn Med; 1976 Oct 29; 83():398-401. PubMed ID: 206058
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Should hyperlipoproteinemia be treated in patients with coronary artery disease?
    Rider AK.
    JAMA; 1975 Jul 21; 233(3):275-7. PubMed ID: 168412
    [No Abstract] [Full Text] [Related]

  • 33. [Dyslipidemia in renal failure].
    Fujioka T, Ueno T, Matsumoto T, Watanabe H.
    Nihon Rinsho; 2004 Jun 21; 62 Suppl 6():118-23. PubMed ID: 15250280
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Plasma glycosaminoglycans in patients with coronary disease and hyperlipidemia].
    Giannini SD, Strunz CM, Forti N, Credidio Rde A, Diament J, Dereviacki BE, de Góis JM, de Serro-Azul LG.
    Arq Bras Cardiol; 1986 May 21; 46(5):307-10. PubMed ID: 3471185
    [No Abstract] [Full Text] [Related]

  • 36. Hyperlipidemia.
    Sloan RW.
    Am Fam Physician; 1983 Sep 21; 28(3):171-82. PubMed ID: 6613796
    [Abstract] [Full Text] [Related]

  • 37. [Lipid lowering: myth or therapeutic necessity?].
    Dtsch Med Wochenschr; 1998 Oct 02; 123(40 Suppl):2-8. PubMed ID: 9793486
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Should hyperlipidemia be treated? Available agents and clinical results.
    Gotto AM.
    Cardiovasc Res Cent Bull; 1978 Oct 02; 17(1):3-27. PubMed ID: 223761
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.